EU clears addition of cardiovascular benefits in labeling for canagliflozin
The European Commission has granted approval for the addition of positive cardiovascular outcomes data on the label of canagliflozin (Invokana, Vokanamet, Janssen). It can be now marketed for the prevention of major cardiovascular events as well as an oral hypoglycemic agent for adults with type 2 diabetes and a history of cardiovascular disease or at least two cardiovascular risk factors.
To continue reading this article
Continue reading your article with a eMediNexus account.